MIRA INFORM REPORT

 

 

Report Date :

24.09.2013

 

IDENTIFICATION DETAILS

 

Name :

MEGA  LIFESCIENCES  PUBLIC  COMPANY  LIMITED

 

 

Formerly Known As :

MEGA  LIFESCIENCES  LIMITED

 

 

Registered Office :

384  Moo  4,  soi  6,  Pattana  3  Road, Bangpoo  Industrial  Estate, T.  Praeksa,   A.  Muang, Samutprakarn   10280

 

 

Country :

Thailand

 

 

Financials (as on) :

31.12.2012

 

 

Date of Incorporation :

15.01.1982

 

 

Com. Reg. No.:

0107556000221

 

 

Legal Form :

Public  Limited  Company

 

 

Line of Business :

Manufacturing,  marketing,  selling  and  distributing  of  medicines  and  other  related  products  under  its  own  brands  “MEGA”.

 

 

No. of Employees :

500

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

Usually correct

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Thailand

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

THAILAND - ECONOMIC OVERVIEW

 

With a well-developed infrastructure, a free-enterprise economy, generally pro-investment policies, and strong export industries, Thailand achieved steady growth due largely to industrial and agriculture exports - mostly electronics, agricultural commodities, automobiles and parts, and processed foods. Thailand is trying to maintain growth by encouraging domestic consumption and public investment to offset weak exports in 2012. Unemployment, at less than 1% of the labor force, stands as one of the lowest levels in the world, which puts upward pressure on wages in some industries. Thailand also attracts nearly 2.5 million migrant workers from neighboring countries. The Thai government is implementing a nation-wide 300 baht ($10) per day minimum wage policy and deploying new tax reforms designed to lower rates on middle-income earners. The Thai economy has weathered internal and external economic shocks in recent years. The global economic crisis severely cut Thailand's exports, with most sectors experiencing double-digit drops. In 2009, the economy contracted 2.3%. However, in 2010, Thailand's economy expanded 7.8%, its fastest pace since 1995, as exports rebounded. In late 2011 growth was interrupted by historic flooding in the industrial areas in Bangkok and its five surrounding provinces, crippling the manufacturing sector. Industry recovered from the second quarter of 2012 onward with GDP growth at 5.5% in 2012. The government has approved flood mitigation projects worth $11.7 billion, which were started in 2012, to prevent similar economic damage, and an additional $75 billion for infrastructure over the next seven years with a plan to start in 2013.

Source : CIA


 

COMPANY NAME

 

MEGA  LIFESCIENCES  PUBLIC  COMPANY  LIMITED

[FORMER : MEGA  LIFESCIENCES  LIMITED]

 

 

SUMMARY

 

BUSINESS  ADDRESS                          :           384  MOO  4,  SOI  6,  PATTANA  3  ROAD,  

BANGPOO  INDUSTRIAL  ESTATE,

T.  PRAEKSA,   A.  MUANG,  

SAMUTPRAKARN   10280

TELEPHONE                                        :           [66]  2324-0681,  2709-3600-4                            

FAX                                                      :           [66]  2324-0451,  2324-0537

E-MAIL  ADDRESS                               :           info.th@megawecare.com        

                                                                        info@medicapltd.com

REGISTRATION  ADDRESS                  :           SAME  AS  BUSINESS  ADDRESS

 

ESTABLISHED                                    :           1982    

REGISTRATION  NO.                           :           0107556000221  [Former : 0105525001721]

TAX  ID  NO.                                         :           3101206166      

CAPITAL REGISTERED                        :           BHT.   436,950,941

CAPITAL PAID-UP                                :           BHT.   367,730,600

SHAREHOLDER’S  PROPORTION        :           THAI            :   87.51%

                                                                        FOREIGN    :   12.49%

FISCALYEAR CLOSING DATE              :           DECEMBER  31           

LEGAL  STATUS                                 :           PUBLIC  LIMITED  COMPANY   

EXECUTIVE                                        :           MR.  VIVEK  DHAWAN,  THAI

                                                                        CHIEF  EXECUTIVE  OFFICER 

NO.  OF  STAFF                                   :           500         

LINES  OF  BUSINESS                        :           MEDICINES  AND  OTHER  RELATED  PRODUCTS 

                                                                        MANUFACTURER,  CONTRACTOR AND  EXPORTER

           

 

CORPORATE  PROFILE

 

OPERATING  TREND                            :           STABLE                       

PRESENT  SITUATION                         :           OPERATING  NORMALLY

REPUTATION                                       :           GOOD  WITH  NORMAL BUSINESS  ENGAGEMENT

MANAGEMENT  STANDARD                 :           MANAGEMENT  WITH  GOOD  PERFORMANCE                       

 

 


 

HISTORY

 

The  subject  was  established on  January  15,  1982  as  a   private  limited  company under  the  registered name “Vidas  Ltd.” by  Thai-Indian  groups,  in order  to  bring  new  technology  in  Thailand  for  manufacturing  Soft  Gelatin  Capsules.  Later,  the  name  was  changed  to  “Medicap  Limited”  and  “Mega  Lifesciences  Limited” on  October 15, 1982 and August 15, 2005,  respectively. 

 

On  March  14,  2013,  the  subject’s  status  was  changed  to  public  limited  company,  namely  MEGA  LIFESCIENCES  PUBLIC  COMPANY  LIMITED. Presently,  its  business  has  expanded  to  produce  various  medicines  and  other  related  products.   It  currently  employs  approximately  500  staff.

 

At  present,  the  subject  is  a  subsidiary  of  Unistretch  Co.,  Ltd.,  Thailand,  which  is  holding  around  58.92%  of  the subject’s  shares.

 

The  subject  now  ranks  among  the  world  class  producers  of  pharmaceutical,  health  food  supplements,  herbal  products,  vitamins,  minerals  and  cosmetic  products  in  the   dosage  form. It  is  also  a  member  of  Pharmaceutical  Producers  Association [PPA].

 

 

AWARD  AND  QUALITY  :  Certified  by 

 

·       TGA  -  Australia

·       FDA  -  Thailand

·       Danish  Health  Authorities 

·       ISO  9002

 

The  subject’s  registered  address  is  384  Moo  4,  Soi  6,  Pattana  3  Rd.,  Bangpoo  Industrial  Estate,  T. Praeksa,  A. Muang,  Samutprakarn 10280,  and  this  is  the  subject’s  current  operation  address.

 

 

THE  BOARD  OF  DIRECTORS

 

      Name

 

Nationality

Age

 

 

 

 

Mr.  Meechai  Viravaidhya

 

Thai

72

Mr. Alan,  Chi Yim  Kam

 

Thai

57

Mr. Manu  Sawangchaeng

 

Thai

62

Mr. Tor  Santisiri

 

Thai

61

Mr. Kirit  Shah

[x]

Thai

60

Mr. Ishaan  Shah

 

Thai

25

Ms. Sameera  Shah

 

Thai

30

Mr. Shiraz  Erach  Poonevala

 

Indian

49

Mr.  Vivek  Dhawan   

[x] :  Chairman

Thai

52

Mr.  Thomas  Abraham 

[x]

Indian

50

 

 

 

 

AUTHORIZED  PERSON

 

Anyone  of  the  above  directors  [x]  can  sign  on  behalf  of  the  subject  with  company’s  affixed.

 

 

MANAGEMENT

 

Mr.  Vivek  Dhawan  is  the  Chief  Executive  Office

He  is  Thai  nationality  with  the  age  of  52  years  old.

 

Mr. Thomas  Abrahum  is  the  Chief  Finance  Officer.

He  is  Indian  nationality  with  the  age  of  50  years  old.

 

Mr.  Apichai  Chancharusiri  is  the  Manufacturing  Director.

He  is  Thai  nationality  with  the  age  of  58  years  old.

 

Mr. Reddy  Jonnala  Venkatahubba  is  the  Operation  Director.

He  is  Indian  nationality.

 

Ms. Chamaiporn  Siritemboon  is  the  Business  Development  Manager.

She  is  Thai  nationality.

 

Mr. Rahul  Deore  is  the  Product  Development  Manager.

He  is  Indian  nationality.

 

Ms. Jintana  Luenglungjakorn  is  the  Purchasing  Manager.

She  is  Thai  nationality.

 

Mr. Pornchai  Wongpayak  is  the  Quality  Control  Director.

He  is  Thai  nationality.

 

Mr. Snehal  Mehta  is  the  Q.A.  &  Regulatory  Affairs  Director.

He  is  Indian  nationality.

 

 

BUSINESS  OPERATIONS

 

The  subject  is  engaged  in  manufacturing,  marketing,  selling  and  distributing  of  medicines  and  other  related  products  under  its  own  brands  “MEGA”,  which  can  be  divided  into  4  categories,  as  follows:

 

  • Complementary  Medicines 

-          Children

-          Diabetics

-          Heart  health

-          Herbals

-          Joint  health

-          Liver  tonic

-          Mega  we  care  

-          Men’s  health

-          Skin  care

-          Slimming

-          Sports  supplements

-          Well-being

-          Women’s  health

  • OTC [Over  The  Counter]

-          Analgesics & NSAIDS

-          Cold  and  cough  remedies

-          Gastrointestinal  disorders

  • Pharma

-          Cardiology

-          Dermatology

-          Gastroenterology

-          Ortho

-          Respiratory

-          Urology

  • Soft  Gelatin  Products

 

The  subject  also  provides  manufacturing  service  of  the  products  under  various  customer’s  brands.

 

MAJOR  BRANDS

 

“SCOTT’S” - Cod  Liver  Oil 

Customer’s  Brand

“MEDICRAFTS”, 

Customer’s  Brand

“MISTINE”, 

Customer’s  Brand

“GIFFARINE”  -  Evening Primrose Oil

Customer’s  Brand

“IMUGINS”  - Schumit  Ginseng

Customer’s  Brand

“GR  150”  -  Schumit  Ginseng  

Customer’s  Brand

“ROCHE”  -  Cough  Medicine

Customer’s  Brand

“SMITH  K-TINE”   

Customer’s  Brand

“BEECHAM”  -  Fish  Liver  Oil

Customer’s  Brand

“LYNAC”

Customer’s  Brand

 etc.

 

 

PRODUCTION

 

1.5  billion  capsules/annum

 

IMPORT  [COUNTRIES]

 

Most  of  raw  materials  and  chemicals  are  imported  from  Japan,  Korea, Hong Kong,  India,  Republic of  China,  Singapore,  France,  Australia,  United  Kingdom,  Germany,  United States  of  America  and  Taiwan.

 

MAJOR  SUPPLIERS

 

Name

Country

Products 

 

 

 

Roche  [Thailand] Co., Ltd.

Thailand

Chemicals

Sanofi   [T]  Ltd.

Thailand

Chemicals

B.A.S.F.  [Thai]  Co., Ltd.

Thailand

Chemicals

Medicap  Pharmacies  Inc.

U.S.A.

Chemicals

Mega  Lifesciences  [Australia]  Pty.  Ltd.

Australia

Chemicals

 

EXPORT  [COUNTRIES]

 

60%  of  the  products  is  exported  to  Hong  Kong,  South  Africa,  Australia,  Singapore,  Philippines,  United  States  of  America, United  Kingdom, Taiwan,  Korea,  Canada,  Republic  of  China,  Nigeria,  Peru  and  India. 

 

SALES  [LOCAL]

 

40%  of  the  products  is  sold  locally  to  manufacturers,  wholesalers,  Thai  Government  and  end-users.

 

MAJOR  CUSTOMERS

 

Name

Country

 

 

Smithkline  and  Beecham

Singapore

Pan  Laboratories

Australia

Berlin  Pharmaceutical Co.,  Ltd.

Thailand

Bioconcept  Co., Ltd.

Thailand

Mega  Products  Co.,  Ltd.

Thailand

Roche  [Thailand]  Co.,  Ltd.

Thailand

Sky  Line  Unity  Co.,  Ltd.

Thailand

Betterway  [Thailand]  Co.,  Ltd.

Thailand

Ceutic  Co.,  Ltd.

Thailand

Mega  Lifesciences  Nigeria  Ltd.

Nigeria

Mega  Lifesciences  [Australia]  Pty. Ltd.

Australia

Mega  Lifesciences Pvt.  Ltd.

India

Mega  Lifesciences  Pty  Peru  S.A.C.

Peru

Mega  Lifesciences  Pty.  Ltd.

Thailand

Maxcare  Ltd.

Thailand

 

 

PARENT  COMPANY

 

Unistretch  Co.,  Ltd.

Address  :  8/23, 8/35-38,  Kathe  House,  North  Sathorn  Rd.,  Bangrak,  Bangkok  10500

 

 

SUBSIDIARIES  &  AFFILIATED  COMPANIES

 

Natural  Health  Foods  Co.,  Ltd.

Business  Type:  Distributor  of  health  food  products

Investment        :  99.99 %  held  by  the  subject.

 

Mega  Lifescience  Pty.  Ltd.

Business  Type:  Distributor  of  pharmaceutical  and  health  products

Investment        :  99.99 %  held  by  the  subject.

 

LITIGATION

 

Bankruptcy  and  Receivership

 

There  are  no  litigation  on  bankruptcy  and  receivership  cases  filed  against  the  subject  found  at  Legal  Execution Department  for  the  past  five  years.

 

Others

 

There  are  no  legal  suits  filed  against   the  subject  for  the  past  two  years.

 

 

CREDIT  

 

Sales  are  by  cash  or  on  the  credits  term  of  30-60   days.

Local  bills  are  paid  by  cash  or  on  the  credits  term  of  30-60  days.

Imports  are  by  L/C  at  sight  or  T/T.

Exports  are  against  L/C  at  sight  or   T/T.

 

 

BANKING

 

Bangkok  Bank  Public  Co.,  Ltd.        

[Head  Office :  333  Silom  Rd.,  Silom,  Bangrak,  Bangkok  10500]

 

The  Siam  Commercial  Bank  Public  Co., Ltd.

[Head Office :  9  Ratchadapisek Rd.,  Ladyao,  Jatujak,  Bangkok  10900]

 

Export  Import  Bank  of  Thailand

[Head Office :  1193  Phaholyothin  Rd.,  Samsennai,  Phyathai,  Bangkok  10400]

 

Kasikornbank  Public  Co.,  Ltd.

 

 

EMPLOYMENT

 

The  subject  employs  approximately  500  staff.  [office  staff  and  factory  workers]

 

 

LOCATION  DETAILS

 

The  premise  is  owned  for  operating  office  and  factory  I  on  4,800  square  meters  at  the  heading  address  in  industrial  area.

 

Factory II: 

 

515  Moo  4,  Pattana 3 Rd., Bangpoo Industrial Estate, T. Praeksa,  A. Muang,  Samutprakarn  10280.

 

Bangkok  Branch:

 

10th  Floor,  Ample  Tower,  120  Moo  11,  Bangna-Trad  Rd.,  Bangna,  Bangkok  10260.

 

 

COMMENT

 

Mega  Lifesciences  Public  Company  Limited  was   incorporated  by  group  of  medicine producers  to  bring  new  technology  in  Thailand  for  manufacturing  soft  gelatin  capsules.  The  company  has  evolved  over  the  years  to  become  a  leader  in  South  East  Asia for  innovation  and  development  in  this  field. It  is  commented  by  an  pharmaceutical  expert  that  Mega  Lifesciences  Public  Company  Limited has a large  more  modern  research and  development  division  compared  with  other  local  pharmaceutical  companies  as  well.

 

The   company  now  ranks  among  the  world  class  producers  of  pharmaceuticals,  health   food  supplements,  herbal  products,  vitamins  &  minerals  and  cosmetic  products  in  this  dosage  form.  It  strives  to  excel  in  product  &  technology  development  and  setting  standards  in  the  international  markets  for  high  quality  products  made  in  a  modern  GMP  approved  plant. 

 

The  company  has  a  well  established  track  record  of  building  brands   and  enjoy  a leadership  status  in  many  international  markets.   Its  business  is  solid  and  continued  growing.

 

 

FINANCIAL  INFORMATION

 

The  capital  was  registered  at  Bht.  5,000,000  divided  into 5,000  shares  of  Bht.  1,000  each.

 

The  capital  was  increased   later  as  followings :

 

            Bht.  10,000,000  on   October  15,  1982

            Bht.  25,000,000  on   April  11,  1986

            Bht.  47,500,000  on   April  24,  1996

            Bht.  50,000,000  on   November  23,  1998

            Bht.  61,000,000  on   December  27,  2000

            Bht.  67,056,190  on   December  30,  2003

 

On  July  18,  2013,  the  registered  capital  was  increased  to  Bht.  436,950,941  divided  into  873,901,882  shares  of  Bht.  0.50  each,  with  the  current  capital  paid-up at  Bht.  367,730,600  or   Bht.  0.50  @ 735,461,200 shares.


 

MAIN  SHAREHOLDERS  :  [as  at  July  18,  2013]  at  Bht.  735,461,200  of  capitalization.

 

NAME

HOLDING

%

 

 

 

Unistretch  Co.,  Ltd.

Nationality:  Thai

Address    :   8/23, 8/35-38  North  Sathorn  Rd.,

                     Silom,  Bangrak,  Bangkok

433,311,400

58.92

Mr.  Vivek  Dhawan

Nationality:  Thai

Address    :   35/166  Srinakarin  Rd.,  Bangkaew,

                     Bangplee,  Samutprakarn

   72,813,580

9.90

Globex  Corporation  Limited

Nationality:  Thai

Address    :   8/25  North  Sathorn  Rd.,  Silom,

                     Bangrak,  Bangkok

   27,689,360

3.76

Mr.  Ishaan  Shah

Nationality:  Thai

Address    :   35/45  Soi  Sukhumvit  11, 

                     Klongtoeynua,  Wattana,  Bangkok

21,717,140

  2.95

Ms. Nishita  Shah

Nationality:  Thai

Address    :   35/42  Soi  Sukhumvit  11, 

                     Klongtoeynua,  Wattana,  Bangkok

21,717,140

  2.95

Ms. Sameera  Shah

Nationality:  Thai

Address    :   34/42  Soi  Sukhumvit  11, 

                    Klongtoeynua,  Wattana,  Bangkok

21,717,140

  2.95

Mr.  Paramjit  Singh  Sawney

Nationality:  Indian

Address    :   384  Moo  4,  Praeksa,  Muang,

                     Samutprakarn

18,203,300

  2.48

Mr.  Sudhir  Gandhi

Nationality:  Indian

Address    :   384  Moo  4,  Praeksa,  Muang,

                     Samutprakarn

18,203,300

  2.48

Mr.  Thomas  Abraham

Nationality:  Indian

Address    :   384  Moo  4,  Praeksa,  Muang,

                     Samutprakarn

18,203,300

2.48

Ms.  Duangnapa  Tongsiri

Nationality:  Thai

Address    :   566  Soi  Raewadee,  Samsennai, 

                     Phyathai,  Bangkok

18,203,300

  2.48

Other  Shareholders

   63,682,240

8.65

 

Total  Shareholders  :   65


 

Share  Structure  [as  at  July  18,  2013]

 

Nationality

Shareholders

No. of  Share

% Shares

 

 

 

 

Thai

27

643,583,600

87.51

Foreign - Indian 

38

91,877,600

12.49

 

Total

 

65

 

735,461,200

 

100.00

 

NAME  OF  AUDITOR  &  CERTIFIED  PUBLIC  ACCOUNTANT  NO. :

 

Mrs. Vilai  Buranakittisophon   No. 3920

 

 

BALANCE SHEET [BAHT]

 

The  latest  financial  figures  published  for  December  31,  2012,  2011  &  2010  were:

          

ASSETS

                                                                                                 

Current Assets

2012

2011

2010

 

 

 

 

Cash  and Cash Equivalents

3,465,365

3,517,784

1,426,967

Trade  Accounts  Receivable    

509,398,817

323,085,007

291,063,064

Other  Receivable

7,383,455

12,718,008

-

Inventories                               

339,643,793

275,495,717

169,697,814

Other  Current  Assets                  

24,291,417

25,577,210

11,906,155

 

 

 

 

Total  Current  Assets                

884,182,847

640,393,726

474,094,000

 

Investment  in Subsidiaries

 

52,162,300

 

52,162,300

 

52,162,300

Cash  at  Bank  pledged  as  a  Collateral

189,285

189,285

 

Fixed Assets                          

394,825,939

265,132,452

268,348,954

Intangible Assets

4,041,934

4,862,281

5,682,627

Advance Payments for Purchase of

   Trademark

 

185,398,986

 

-

 

-

Other  Non-current  Assets

 -

-

24,568

 

Total  Assets                 

 

1,520,801,291

 

962,740,044

 

800,312,449

 


 

LIABILITIES & SHAREHOLDERS' EQUITY [BAHT]

 

Current Liabilities

2012

2011

2010

 

 

 

 

Bank  Overdraft  &  Short-term  Loan  from

  Financial  Institution

 

394,610,615

 

289,681,119

 

242,557,084

Trade  Accounts  Payable

171,800,514

166,314,594

99,988,735

Other Payable 

34,976,384

11,312,030

-

Short-term  Loan & Accrued Interest –

   Related  Company

 

2,554,670

 

2,549,277

 

2,534,884

Current  Portion of  Long-term  Loans

60,455,895

20,255,000

28,410,692

Current  Portion  of  Hire-purchase  Contract

   Liabilities

 

59,858

 

93,734

 

228,805

Accrued  Income  Tax

10,361,945

13,445,232

21,526,188

Accrued Expenses

30,883,656

25,489,953

13,002,248

Other  Current  Liabilities             

-

-

11,025,674

 

 

 

 

Total Current Liabilities

705,703,537

529,140,939

419,274,310

 

Long-term  Loan  from Financial  Institution

 

242,719,105

 

4,430,000

 

24,685,000

Hire-purchase  Contract  Liabilities

219,618

-

95,335

Employee  Benefit  Obligation

36,884,883

31,513,122

-

 

Total  Liabilities            

 

985,527,143

 

565,084,661

 

444,054,645

 

 

 

 

Shareholders' Equity

 

 

 

 

 

 

 

 Share  capital : Baht  10  par  value 

  authorized,  issued  and  fully 

  paid  share  capital  6,705,619  shares

 

 

67,056,190

 

 

67,056,190

 

 

67,056,190

 

 

 

 

Capital  Paid                     

67,056,190

67,056,190

67,056,190

Retained  Earning

  Appropriated  for  Statutory  Reserve

 

7,721,129

 

7,721,129

 

7,721,129

  Unappropriated                  

460,496,829

322,878,664

281,480,485

 

Total Shareholders' Equity

 

535,274,148

 

397,655,983

 

356,257,804

 

Total Liabilities  &  Shareholders'  Equity

 

1,520,801,291

 

962,740,044

 

800,312,449

 

                                                  


 

PROFIT  &  LOSS  ACCOUNT

 

 

Revenue

2012

2011

2010

 

 

 

 

Sales                                         

1,437,162,501

1,116,952,153

1,019,295,271

Investment Income

140,000,000

94,000,000

74,995,650

Interest  Income

 

-

-

Gain  on  Exchange  Rate

1,017,442

-

919,985

Dividend  Income

 

-

-

Other  Income                

14,185,021

8,449,565

4,198,581

 

Total  Revenues           

 

1,592,364,964

 

1,219,401,718

 

1,099,409,487

 

Expenses

 

 

 

 

 

 

 

Cost  of  Goods  Sold                            

1,108,770,629

857,675,395

741,078,330

Selling Expenses

26,487,757

30,256,080

27,615,213

Administrative Expenses

137,851,762

122,364,107

113,002,398

Loss on Exchange Rate

-

4,052,009

-

Financial Cost

13,276,030

11,305,259

11,917,345

 

Total Expenses             

 

1,286,386,178

 

1,025,652,850

 

893,613,286

 

 

 

 

Profit  before Income Tax

305,978,786

193,748,868

205,796,201

Income  Tax

[23,519,251]

[32,160,000]

[40,260,612]

 

Net  Profit / [Loss]

 

282,459,535

 

161,588,868

 

165,535,589

 


 

FINANCIAL  ANALYSIS

 

ITEM

UNIT

2012

2011

2010

 

 

 

 

 

LIQUIDITY RATIO

 

 

 

 

CURRENT RATIO

TIMES

1.25

1.21

1.13

QUICK RATIO

TIMES

0.74

0.64

0.70

 

 

 

 

 

ACTIVITY RATIO

 

 

 

 

FIXED ASSETS TURNOVER

TIMES

3.64

4.21

3.80

TOTAL ASSETS TURNOVER

TIMES

0.95

1.16

1.27

INVENTORY CONVERSION PERIOD

DAYS

111.81

117.24

83.58

INVENTORY TURNOVER

TIMES

3.26

3.11

4.37

RECEIVABLES CONVERSION PERIOD

DAYS

129.37

105.58

104.23

RECEIVABLES TURNOVER

TIMES

2.82

3.46

3.50

PAYABLES CONVERSION PERIOD

DAYS

56.56

70.78

49.25

CASH CONVERSION CYCLE

DAYS

184.63

152.04

138.56

 

 

 

 

 

PROFITABILITY RATIO

 

 

 

 

COST OF GOODS SOLD

%

77.15

76.79

72.70

SELLING & ADMINISTRATION

%

11.43

13.66

13.80

INTEREST

%

0.92

1.01

1.17

GROSS PROFIT MARGIN

%

33.65

32.39

35.15

NET PROFIT MARGIN BEFORE EX. ITEM

%

21.29

17.35

20.19

NET PROFIT MARGIN

%

19.65

14.47

16.24

RETURN ON EQUITY

%

52.77

40.64

46.47

RETURN ON ASSET

%

18.57

16.78

20.68

EARNING PER SHARE

BAHT

42.12

24.10

24.69

 

 

 

 

 

LEVERAGE RATIO

 

 

 

 

DEBT RATIO

TIMES

0.65

0.59

0.55

DEBT TO EQUITY RATIO

TIMES

1.84

1.42

1.25

TIME INTEREST EARNED

TIMES

23.05

17.14

17.27

 

 

 

 

 

ANNUAL GROWTH

 

 

 

 

SALES GROWTH

%

28.67

9.58

 

OPERATING PROFIT

%

57.93

(5.85)

 

NET PROFIT

%

74.80

(2.38)

 

FIXED ASSETS

%

48.92

(1.20)

 

TOTAL ASSETS

%

57.97

20.30

 

 

 

ANNUAL GROWTH : EXCELLENT

 

An annual sales growth is 28.67%. Turnover has increased from THB 1,116,952,153.00 in 2011 to THB 1,437,162,501.00 in 2012. While net profit has increased from THB 161,588,868.00 in 2011 to THB 282,459,535.00 in 2012. And total assets has increased from THB 962,740,044.00 in 2011 to THB 1,520,801,291.00 in 2012.                 

                       

PROFITABILITY : IMPRESSIVE

 

PROFITABILITY RATIO

 

Gross Profit Margin

33.65

Deteriorated

Industrial Average

146.93

Net Profit Margin

19.65

Impressive

Industrial Average

3.82

Return on Assets

18.57

Impressive

Industrial Average

7.09

Return on Equity

52.77

Impressive

Industrial Average

15.67

 

Gross Profit Margin used to assess a firm's financial health by revealing the proportion of money left over from revenues after accounting for the cost of goods sold. Gross profit margin serves as the source for paying additional expenses and future savings. The company's figure is 33.65%. When compared with the industry average, the ratio of the company was lower. This indicated that company may have problems with control over its costs.

 

Net Profit Margin is the indicator of the company's efficiency in that net profit takes into consideration all expenses of the company. A low profit margin indicates a low margin of safety, higher risk that a decline in sales will erase profits and result in a net loss. The company's figure is 19.65%, higher figure when compared with those of its average competitors in the same industry, indicated that business was an efficient operator  in a dominant position within its industry.

 

Return on Assets measures how efficiently profits are being generated from the assets employed in the business when compared with the ratios of firms in a similar business. A low ratio in comparison with industry averages indicates an inefficient use of business assets. Return on Assets ratio is 18.57%, higher figure when compared with those of its average competitors in the same industry, indicated that business was an efficient profit  in a dominant position within its industry.

 

Return on Equity indicates how profitable a company is by comparing its net income to its average shareholders' equity, ROE measures how much the shareholders earned for their investment in the company. Return on Equity ratio is 52.77%, higher figure when compared with those of its average competitors in the same industry, indicated that business was an efficient profit  in a dominant position within its industry.

 

Trend of the average competitors in the same industry for last 5 years

Return on Assets                       Uptrend

Return on Equity                       Uptrend

 

 

LIQUIDITY : RISKY

 

 

 

LIQUIDITY RATIO

 

Current Ratio

1.25

Acceptable

Industrial Average

1.69

Quick Ratio

0.74

 

 

 

Cash Conversion Cycle

184.63

 

 

 

 

The Current Ratio is to ascertain whether a company's short-term assets are readily available to pay off its short-term liabilities. The company's figure is 1.25 times in 2012, increased from 1.21 times, then it is generally considered to have good short-term financial strength. When compared with the industry average, the ratio of the company was lower.

 

The Quick Ratio is a liquidity indicator that further refines the current ratio by measuring the amount of the most liquid current assets there are to cover current liabilities. The company's figure is 0.74 times in 2012, decreased from 0.64 times, then the company has not enough current assets that presumably can be quickly converted to cash for pay financial obligations.

 

The Cash Conversion Cycle measures the number of days a company's cash is tied up in the production and sales process of its operations and the benefit from payment terms from its creditors. It meant the company could survive when no cash inflow was received from sale for 185 days.

 

Trend of the average competitors in the same industry for last 5 years

Current Ratio                 Uptrend

 

 

LEVERAGE : ACCEPTABLE

 

 

 

LEVERAGE RATIO

 

Debt Ratio

0.65

Acceptable

Industrial Average

0.54

Debt to Equity Ratio

1.84

Risky

Industrial Average

1.10

Times Interest Earned

23.05

Impressive

Industrial Average

(0.65)

 

Debt to Equity Ratio a measurement of how much suppliers, lenders, creditors and obligors have committed to the company versus what the shareholders have committed. A lower the percentage means that the company is using less leverage and has a stronger equity position.

 

Times Interest Earned measuring a company's ability to meet its debt obligations. Ratio is 23.05 higher than 1, so the company can pay interest expenses on outstanding debt.

 

Debt Ratio shows the proportion of a company's assets which are financed through debt. The company's figure is 0.65 greater than 0.5, most of the company's assets are financed through debt.

 

Trend of the average competitors in the same industry for last 5 years

Debt Ratio                                Downtrend

Times Interest Earned                Downtrend

 

ACTIVITY : SATISFACTORY

 

 

ACTIVITY RATIO

 

Fixed Assets Turnover

3.64

Impressive

Industrial Average

(2.69)

Total Assets Turnover

0.95

Acceptable

Industrial Average

1.82

Inventory Conversion Period

111.81

 

 

 

Inventory Turnover

3.26

Satisfactory

Industrial Average

4.30

Receivables Conversion Period

129.37

 

 

 

Receivables Turnover

2.82

Satisfactory

Industrial Average

3.43

Payables Conversion Period

56.56

 

 

 

 

The company's Account Receivable Ratio is calculated as 2.82 and 3.46 in 2012 and 2011 respectively. This ratio measures the efficiency of the company in managing its trade debtors to generate revenue. A lower ratio may indicate over extension and collection problems. Conversely, a higher ratio may indicate an overtly stringent policy. In this case, the company's A/R ratio in 2012 decreased from 2011. This would suggest the company had deteriorated in the management of its debt collections.

 

Inventory Turnover in Days Ratio indicates the liquidity of inventory. It estimates the number of days that it will take to sell the current inventory. Inventory is particularly sensitive to change in business activities. The inventory turnover in days has decreased from 117 days at the end of 2011 to 112 days at the end of 2012. This represents a positive trend. And Inventory turnover has increased from 3.11 times in year 2011 to 3.26 times in year 2012.

 

The company's Total Asset Turnover is calculated as 0.95 times and 1.16 times in 2012 and 2011 respectively. This ratio is determined by dividing total assets into total sales turnover. The ratio measures the activity of the assets and the ability of the firm to generate sales through the use of the assets.

 

Trend of the average competitors in the same industry for last 5 years

Fixed Assets Turnover               Downtrend

Total Assets Turnover                Downtrend

Inventory Turnover                     Uptrend

Receivables Turnover                Uptrend

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.52

UK Pound

1

Rs.100.26

Euro

1

Rs.84.67

 

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.